Compuen (CGEN) Wānana Kūʻai Kūʻai
Hōʻoia AI: CGEN
Hoʻopuka ka AI i kahi kumukūʻai pahuhopu no ka lā kālepa aʻe, ka hopena pule a me ka hopena mahina. Hoʻomākaukau ʻia ka hoʻololi mai ka kumukūʻai hou loa. He helnau kūlana helu wale nō kēia, ʻaʻole he ʻōlelo aʻoaʻo hoʻopukapuka.
Kumukūʻai ma luna o nā mahina 6 i hala
Hōʻike ʻo Premium i nā pahuhopu kumukūʻai o ka AI no 1 lā, 1 pule a me 1 mahina no kēia a me nā stock ʻē aʻe.
Wehe iā Premium🔒 Moʻolelo hōʻike wānana
The forecast track record — every past forecast next to the actual close — is part of Premium.
Wehe iā PremiumE pili ana i kēia Hui
Compugen Ltd. is engaged in the research, development, and distribution of targeted and therapeutic drugs. The company’s portfolio primarily consists of early-stage and preclinical immuno-oncology programs aimed at developing cancer immunotherapies, both as monotherapies and in combination with other drugs. The company is also developing treatments for autoimmune diseases.
